SAFETY OF MISOPROSTOL IN SECOND TRIMESTER MISCARRIAGES IN PATIENTS WITH PREVIOUS UTERINE SCARS

Samina Aliya Sabir, None Shahida Sultan
{"title":"SAFETY OF MISOPROSTOL IN SECOND TRIMESTER MISCARRIAGES IN PATIENTS WITH PREVIOUS UTERINE SCARS","authors":"Samina Aliya Sabir, None Shahida Sultan","doi":"10.52764/jms.23.31.3.14","DOIUrl":null,"url":null,"abstract":"Objective: To assess the safety of Misoprostol in mid-trimester miscarriages in patients with previous scars. Materials and Methods: This was a cross-sectional comparative study conducted in the Department of Gynaecology and Obstetrics, Lady Reading Hospital, from January 2021 to December 2021. Two-hundred patients with second-trimester miscarriages were included in the study. They were divided into two groups, 100 patients with no previous scar as the control group and another 100 patients with a previous scar as the study group. Patients having an incomplete abortion, gestational trophoblastic disease, and more than one scar were excluded from the study. Misoprostol doses were kept vaginally in both groups. The doses were kept according to the gestational period of 13 to 24 weeks following the local protocol which was comparable with the FIGO protocol. Data analysis was done using SPSS-24. Results: The Demographic features of patients of the two groups, were comparable for maternal Age (26±5.3 Years versus 25±4.9 years), Gestational Age in weeks of (18±1.3 weeks versus117±1.6 weeks) Gravidity (4.5±1.6 versus 4.9±1.2) and of Parity (3.4 ±1.4 versus 3.6 ±1.1) which showed no significant difference with respect to age, parity and gestational age. The period needed for successful TOP was 18 hours in the control group whereas it was 36 hours in the scarred uterus with half doses. Successful termination was observed in 61% of the study group with the scared uterus and 72% in the control group. Conclusion: Our study concluded that misoprostol is safe and effective in the termination of second-trimester miscarriages with a scarred uterus. Keywords: Misoprostol, Miscarriage, Previous Uterine Scar","PeriodicalId":16486,"journal":{"name":"Journal of Medical Sciences","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52764/jms.23.31.3.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To assess the safety of Misoprostol in mid-trimester miscarriages in patients with previous scars. Materials and Methods: This was a cross-sectional comparative study conducted in the Department of Gynaecology and Obstetrics, Lady Reading Hospital, from January 2021 to December 2021. Two-hundred patients with second-trimester miscarriages were included in the study. They were divided into two groups, 100 patients with no previous scar as the control group and another 100 patients with a previous scar as the study group. Patients having an incomplete abortion, gestational trophoblastic disease, and more than one scar were excluded from the study. Misoprostol doses were kept vaginally in both groups. The doses were kept according to the gestational period of 13 to 24 weeks following the local protocol which was comparable with the FIGO protocol. Data analysis was done using SPSS-24. Results: The Demographic features of patients of the two groups, were comparable for maternal Age (26±5.3 Years versus 25±4.9 years), Gestational Age in weeks of (18±1.3 weeks versus117±1.6 weeks) Gravidity (4.5±1.6 versus 4.9±1.2) and of Parity (3.4 ±1.4 versus 3.6 ±1.1) which showed no significant difference with respect to age, parity and gestational age. The period needed for successful TOP was 18 hours in the control group whereas it was 36 hours in the scarred uterus with half doses. Successful termination was observed in 61% of the study group with the scared uterus and 72% in the control group. Conclusion: Our study concluded that misoprostol is safe and effective in the termination of second-trimester miscarriages with a scarred uterus. Keywords: Misoprostol, Miscarriage, Previous Uterine Scar
米索前列醇在既往子宫瘢痕患者妊娠中期流产中的安全性
目的:评价米索前列醇治疗有疤痕的中期流产患者的安全性。材料和方法:这是一项横断面比较研究,于2021年1月至2021年12月在雷丁夫人医院妇产科进行。该研究包括了200名中期妊娠流产的患者。他们被分为两组,100名既往无疤痕的患者作为对照组,另外100名既往有疤痕的患者作为研究组。有不完全流产、妊娠滋养细胞疾病和不止一个疤痕的患者被排除在研究之外。两组患者均保持阴道服用米索前列醇剂量。按照与FIGO方案相当的当地方案,按照13至24周的妊娠期保持剂量。数据分析采用SPSS-24软件。结果:两组患者的人口统计学特征在产妇年龄(26±5.3岁vs 25±4.9岁)、胎龄(18±1.3周vs 117±1.6周)、妊娠(4.5±1.6周vs 4.9±1.2周)和胎次(3.4±1.4周vs 3.6±1.1周)方面具有可比性,在年龄、胎次和胎龄方面无显著差异。对照组TOP成功所需的时间为18小时,而疤痕子宫半剂量组为36小时。子宫恐惧组成功终止妊娠的比例为61%,对照组为72%。结论:我们的研究表明,米索前列醇在妊娠中期结疤子宫流产中是安全有效的。关键词:米索前列醇,流产,既往子宫瘢痕
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信